Paul Schimmel
CIK: 0001236447
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
aTYR PHARMA INC
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- May 27, 2026ATYR
aTYR PHARMA INC
Purchase(P)Indirect100K shares at avg. $0.50$50K - May 11, 2026ATYR
aTYR PHARMA INC
Award(A)DirectStock Option (right to buy)
50K shares- - Oct 9, 2025ATYR
aTYR PHARMA INC
Purchase(P)Indirect318K shares at avg. $0.94$299K - Oct 8, 2025ATYR
aTYR PHARMA INC
Purchase(P)Indirect682K shares at avg. $0.90$612K - May 1, 2025ATYR
aTYR PHARMA INC
Award(A)DirectStock Option (right to buy)
50K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| May 27, 2026 | ATYR aTYR PHARMA INC | Purchase(P) | 100,000 | $0.50 | $49,630 | Indirect |
| May 11, 2026 | ATYR aTYR PHARMA INC | Award(A) Stock Option (right to buy) | 50,000 | - | - | Direct |
| Oct 9, 2025 | ATYR aTYR PHARMA INC | Purchase(P) | 317,999 | $0.94 | $299,364 | Indirect |
| Oct 8, 2025 | ATYR aTYR PHARMA INC | Purchase(P) | 682,001 | $0.90 | $612,437 | Indirect |
| May 1, 2025 | ATYR aTYR PHARMA INC | Award(A) Stock Option (right to buy) | 50,000 | - | - | Direct |
1-5 of 5 transactions
About SCHIMMEL PAUL
SCHIMMEL PAUL (SEC CIK 0001236447) files insider reports with the SEC as Director of aTYR PHARMA INC (ATYR).
Signal8 holds 4 ownership filings by SCHIMMEL PAUL, all Form 4s, filed between May 2, 2025 and May 28, 2026. Those filings report 5 transactions, from May 1, 2025 to May 27, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on SCHIMMEL PAUL's filings is in SAN DIEGO, CA.
Recent filings by SCHIMMEL PAUL
- May 27, 2026: Open-market purchase of ATYR shares (Form 4, code P).
- May 11, 2026: Grant or award of ATYR derivative securities (Form 4, code A).
- Oct 9, 2025: Open-market purchase of ATYR shares (Form 4, code P).
- Oct 8, 2025: Open-market purchase of ATYR shares (Form 4, code P).
- May 1, 2025: Grant or award of ATYR derivative securities (Form 4, code A).
Other insiders filing for aTYR PHARMA INC (ATYR)
- Yaras Brandon, Chief Financial Officer
- Coughlin Timothy, Director
- BENEVICH ERIC, Director
- Gross Jane A, Director
- Lucas Svetlana, Director
- Zaknoen Sara, Director